Twelve days after Cochrane said anti-amyloid Alzheimer's drugs probably do not produce clinically meaningful benefit, the payment system is still behaving as though nothing has happened.

FDA has not publicly reset the premise. CMS has not publicly reopened the reimbursement frame. Eisai and Lilly have not answered in the one register that matters to patients who do not live inside neurology conferences: whether Medicare's live coverage arrangement should change when a major evidence review says the class delivers absent or trivial cognitive benefit while increasing brain swelling and bleeding risks. [1]

Sunday's paper argued that Day 11 had made institutional silence the reimbursement story. Monday makes the point less dramatic and more important. A weekend can explain delay. A twelfth day begins to look like governance.

The Cochrane review examined 17 clinical trials covering 20,342 participants with mild cognitive impairment or mild dementia due to Alzheimer's disease. It concluded that amyloid-beta-targeting monoclonal antibodies produced little to no difference in cognitive decline or dementia severity at 18 months, with functional gains small at best, and increased amyloid-related imaging abnormalities. [1]

The controversy is real. The Pharmaceutical Journal reported the finding as evidence that amyloid-targeting drugs are probably not effective, while clinicians critical of the review argue that it pools failed older agents with newer approved drugs and compresses a slowly progressive disease into an 18-month measurement window. [2] Science-Based Medicine called the review controversial but still treated the result as a serious challenge to the therapeutic story built around amyloid clearance. [3]

That scientific fight is not the same as the public payment question. Medicare coverage for Leqembi expanded after FDA traditional approval, under a framework that ties payment to registry participation and real-world evidence collection. [4] That framework was built for uncertainty. It was not built to make uncertainty invisible.

The human stakes are not abstract. Anti-amyloid treatment means infusion visits, MRI monitoring, transport, caregiver time, and the emotional burden of deciding whether a small delay in decline is worth the risk. Families can choose differently. Physicians can read the evidence differently. Public insurance cannot pretend the dispute is a private preference.

This is the divergence. Mainstream medical coverage is still litigating whether Cochrane interpreted the trials properly. Health X has moved faster to the payer question: if the drug class has no clinically meaningful effect by a gold-standard review, why does reimbursement continue without a public answer?

The better institutional response would not be a press release declaring the drugs dead. It would be a memo that says what standard of evidence justifies continuing payment, what evidence would narrow it, and whether the registry can answer the question the review sharpened. That is not a hostile act toward patients. It is the minimum respect owed to them.

Silence is easier. It lets manufacturers defend their products in the scientific register, lets clinicians proceed case by case, and lets CMS avoid becoming the villain in a disease defined by desperation. But silence also pushes the decision onto families at the clinic door while the public payer keeps the channel open.

The registry framework was supposed to make that burden lighter by turning coverage into learning. If that is still the defense, CMS should say so. If the registry is not designed to answer Cochrane's objection, CMS should say that too. A public payer cannot outsource its epistemology to infusion suites.

Nor can FDA and the manufacturers hide behind the difference between approval and payment. Approval asks whether a drug can be sold under a risk-benefit standard. Payment asks whether public money should underwrite its routine use. Those are related questions, not identical ones. The Cochrane review presses the second question because it describes population benefit and population harm in the same breath. [1]

For a family, the silence arrives as fog. The clinician can explain the controversy, the label, the monitoring, and the hope. The insurer can process the claim. But nobody in authority has publicly reconciled the review with the reimbursement lane. That leaves the sickest institutionally burdened people in the system to perform the policy analysis themselves.

Day 12 is therefore not a new drug story. It is a reimbursement story. The institutions do not have to agree with Cochrane. They do have to say why the payment system should keep acting as if Cochrane did not speak.

-- NORA WHITFIELD, Chicago